ESMO guidelines in advanced NSCLC
2016
Rolf Stahel
University Hospital of Zürich
1 |
Seoul, 28.10.2016
ESMO clinical practice guidelines in metastatic non-
small cell lung cancer: Squamous cell carcinoma
2 |
Novello et al,
Ann Oncol 2016
ESMO clinical practice guidelines in metastatic non-
small cell lung cancer: Squamous cell carcinoma
3 |
Novello et al,
Ann Oncol 2016
Levels of evidence and grade of recommendation4 |
Adapted from the Infectious Diseases Society of America -United States Public Health Service Grading
System. Clin Infect Dis 2001;33:139 –144
Magnitunde of Clinical Benefit Scale: Form 2a
(primary endpoint OS, OS < 1 year, non-curative)
5 |
Cherny et al, Ann Oncol 2015
5
4
3
2
1
A
B
C
Curative Non-curative
Magnitunde of Clinical Benefit Scale: Second line
squamous cell carcinoma
6 |
ESMO clinical practice guidelines in metastatic non-
small cell lung cancer: Non-squamous cell carcinoma
7 |
Novello et al,
Ann Oncol 2016
ESMO clinical practice guidelines in metastatic non-
small cell lung cancer: Non-squamous cell carcinoma
8 |
Novello et al,
Ann Oncol 2016
Magnitunde of Clinical Benefit Scale: Second line
non-squamous cell carcinoma
9 |
ESMO clinical practice guidelines in metastatic
non-small cell lung cancer: Activating EGFR mutation
10 |
Novello et al,
Ann Oncol 2016
Magnitude of Clinical Benefit Scale;: Erlotinib and
bevacizumab for EFGR mutated NSCLC
11 |
ESMO clinical practice guidelines in metastatic non-
small cell lung cancer: Activating EGFR mutation
12 |
Novello et al,
Ann Oncol 2016
ESMO clinical practice guidelines in metastatic non-
small cell lung cancer: ALK translocation
13 |
Novello et al,
Ann Oncol 2016
KEYNOTE-024: Pembrolizumab vs platinum-based chemotherapyas first-Line therapy for advanced NSCLC with a PD-L1 TPS ≥50%Martin Reck,1 Delvys Rodríguez-Abreu,2 Andrew G. Robinson,3 Rina Hui,4 Tibor Csőszi,5 Andrea
Fülöp,6 Maya Gottfried,7 Nir Peled,8 Ali Tafreshi,9 Sinead Cuffe,10 Mary O’Brien,11 Suman Rao,12
Katsuyuki Hotta,13 Melanie A. Leiby,14 Gregory M. Lubiniecki,14 Yue Shentu,14 Reshma Rangwala,14 and
Julie R. Brahmer15on behalf of the KEYNOTE-024 investigators
14 |
KEYNOTE-024: Pembrolizumab vs platinum-based chemotherapyas first-Line therapy for advanced NSCLC with a PD-L1 TPS ≥50%Martin Reck,1 Delvys Rodríguez-Abreu,2 Andrew G. Robinson,3 Rina Hui,4 Tibor Csőszi,5 Andrea
Fülöp,6 Maya Gottfried,7 Nir Peled,8 Ali Tafreshi,9 Sinead Cuffe,10 Mary O’Brien,11 Suman Rao,12
Katsuyuki Hotta,13 Melanie A. Leiby,14 Gregory M. Lubiniecki,14 Yue Shentu,14 Reshma Rangwala,14 and
Julie R. Brahmer15on behalf of the KEYNOTE-024 investigators
15 |
Primary analysis from OAK, a randomized phase III study comparing atezolizumab with docetaxel in advanced NSCLCFabrice Barlesi, Keunchil Park, Fortunato Ciardiello, Joachim von Pawel, Shirish Gadgeel, Toyoaki
Hida, Dariusz Kowalski, Manuel Cobo Dols, Diego Cortinovis, Joseph Leach, Jonathan Polikoff, David
R. Gandara, Carlos Barrios, Daniel Chen, Pei He, Marcin Kowanetz, Marcus Ballinger, Daniel
Waterkamp, Alan Sandler, Achim Rittmeyer
16 |
Primary analysis from OAK, a randomized phase III study comparing atezolizumab with docetaxel in advanced NSCLCFabrice Barlesi, Keunchil Park, Fortunato Ciardiello, Joachim von Pawel, Shirish Gadgeel, Toyoaki
Hida, Dariusz Kowalski, Manuel Cobo Dols, Diego Cortinovis, Joseph Leach, Jonathan Polikoff, David
R. Gandara, Carlos Barrios, Daniel Chen, Pei He, Marcin Kowanetz, Marcus Ballinger, Daniel
Waterkamp, Alan Sandler, Achim Rittmeyer
17 |
18 |
ETOP | Name Project | Title Presentation | Zurich, July 27, 2009